Former FDA Official Calls For 483 Reforms, Notes Caveats
Executive Summary
Public scrutiny has made 483 results much more impactful than intended, says Howard Sklamberg, former FDA deputy commissioner for global regulatory operations and policy. He reminds stakeholders that information in them is preliminary.
You may also be interested in...
Former FDA official Sklamberg On Objectivity In 483s, Assessing Quality Culture
Former US FDA Deputy Commissioner for Global Regulatory Operations and Policy, Howard Sklamberg, shares his views at a conference in India on a range of issues, including the need for formal policy mechanisms to help infuse improved objectivity around Form 483 observations and challenges on evaluating quality culture.
US FDA Threatens Fines For ClinicalTrials.gov Noncompliance
Draft guidance states that "responsible parties" could be fined $10,000 for not submitting trial information to the federal data repository as required by law.
FDA Warns Apotex Management To Demand Quality, Meet Specs
Apotex warning letter reflects FDA’s emphasis on company-wide quality systems and invalidated OOS results.